Remdesivir
featured

We will be closed during Nov. 25-28 for observance of thanksgiving. Orders received during Nov 24-28 will be shipped on Nov 29

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329511

CAS#: 1809249-37-3 (free base)

Description: Remdesivir, also known as GS-5734, is a prodrug form of the antiviral nucleoside analog GS-44152. Upon entry into cells, remdesivir is metabolized into the nucleotide triphosphate GS-441524. Remdesivir inhibits murine hepatitis virus (MHV) with an EC50 of 30 nM, and blocks SARS-CoV and MERS-CoV in HAE cells with EC50s of both 74 nM in HAE cells after treatment for 24 h. GS-5734 inhibits both epidemic and zoonotic coronaviruses. It was developed as a treatment for filovirus infections such as Ebola virus disease and Marburg virus. Remdesivir was approved for treatment of COVID-19. ******* WARNING****** Our product Remdesivir is a Pure chemical in Powder form for laboratory research use only, NOT FOR HUMAN OR PATIENT USE


Chemical Structure

img
Remdesivir
CAS# 1809249-37-3 (free base)

Theoretical Analysis

MedKoo Cat#: 329511
Name: Remdesivir
CAS#: 1809249-37-3 (free base)
Chemical Formula: C27H35N6O8P
Exact Mass: 602.2254
Molecular Weight: 602.58
Elemental Analysis: C, 53.82; H, 5.85; N, 13.95; O, 21.24; P, 5.14

Price and Availability

Size Price Availability Quantity
50.0mg USD 115.0 Ready to ship
100.0mg USD 195.0 Ready to ship
200.0mg USD 350.0 Ready to ship
500.0mg USD 750.0 Ready to ship
1.0g USD 1250.0 Ready to ship
2.0g USD 1950.0 Ready to ship
5.0g USD 3850.0 Ready to ship
10.0g USD 5350.0 Ready to ship
20.0g USD 7450.0 Ready to ship
Click to view more sizes and prices
Bulk inquiry

Related CAS #: 1809249-37-3 (free base)   2250110-53-1 (maleate)  

Synonym: Remdesivir; GS-5734; GS 5734; GS5734, Prodrug of GS-441524; Prodrug of GS441524; Prodrug of GS441524;

IUPAC/Chemical Name: 2-ethylbutyl ((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate

InChi Key: RWWYLEGWBNMMLJ-YSOARWBDSA-N

InChi Code: InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1

SMILES Code: C[C@H](N[P@@](OC1=CC=CC=C1)(OC[C@H]2O[C@@](C#N)(C3=CC=C4C(N)=NC=NN43)[C@H](O)[C@@H]2O)=O)C(OCC(CC)CC)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Biological target: Nucleoside analogue with effective antiviral activity and is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro.
In vitro activity: In vitro, Remdesivir (RDV) exhibited antiviral activity against a clinical isolate of SARS-CoV-2 in primary human airway epithelial cells with a half-maximal effective concentration of 9.9 nM and also potently (280 nM) inhibited SARS-CoV-2 replication in Calu-3 human lung cells. In biochemical assays assessing RDV-triphosphate incorporation by the SARS-CoV-2, SARS-CoV, and MERS-CoV viral RNA-dependent RNA polymerase complexes, RDV triphosphate was selectively incorporated over the natural nucleotide substrate adenosine triphosphate and inhibited viral RNA synthesis with a half-maximal inhibitory concentration value of 32 nM for MERS-CoV. Reference: Clin Pharmacokinet. 2021 Mar 30 : 1–15. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007387/
In vivo activity: In vivo, Remdesivir (RDV) showed therapeutic efficacy in SARS-CoV-2-infected rhesus monkeys and prophylactic and therapeutic efficacy in MERS-CoV-infected rhesus monkeys. Briefly, 12 h after inoculation with SARS-CoV-2, rhesus monkeys received an RDV 10-mg/kg IV loading dose followed by maintenance doses of RDV 5 mg/kg at 24 h post-inoculation and once daily thereafter for a total of 6 days of treatment. The aim of the loading dose was to rapidly generate high GS-443902 concentrations following the first dose. Treatment with this regimen resulted in a significant reduction in clinical signs of respiratory disease, lung pathology and gross lung lesions, and viral RNA levels compared with vehicle-treated animals. Reference: Clin Pharmacokinet. 2021 Mar 30 : 1–15. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007387/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 100.0 165.95
Ethanol 12.0 20.0

Preparing Stock Solutions

The following data is based on the product molecular weight 602.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Formulation for in vivo study

Option 1: (1). Formulation for in vivo study (Author from NIH): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104368/ ....treated with 5 mg/kg remdesivir in vehicle solution (5 mg/mL 12% sulfobutylether-β-cyclodextrin in water and hydrochloric acid, pH3.5)
Option 2: (2). Formulation for in vivo study ( Author from CDC) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732787/ One group of animals received remdesivir (10 mg/kg) (Gilead Sciences) in vehicle solution [12% sulfobutylether-β-cyclodextrin in water and hydrochloric acid (pH 3.5)]
Formulation protocol: 1. Humeniuk R, Mathias A, Kirby BJ, Lutz JD, Cao H, Osinusi A, Babusis D, Porter D, Wei X, Ling J, Reddy YS, German P. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. Clin Pharmacokinet. 2021 Mar 30:1–15. doi: 10.1007/s40262-021-00984-5. Epub ahead of print. PMID: 33782830; PMCID: PMC8007387. 2. Buckland MS, Galloway JB, Fhogartaigh CN, Meredith L, Provine NM, Bloor S, Ogbe A, Zelek WM, Smielewska A, Yakovleva A, Mann T, Bergamaschi L, Turner L, Mescia F, Toonen EJM, Hackstein CP, Akther HD, Vieira VA, Ceron-Gutierrez L, Periselneris J, Kiani-Alikhan S, Grigoriadou S, Vaghela D, Lear SE, Török ME, Hamilton WL, Stockton J, Quick J, Nelson P, Hunter M, Coulter TI, Devlin L; CITIID-NIHR COVID-19 BioResource Collaboration; MRC-Toxicology Unit COVID-19 Consortium, Bradley JR, Smith KGC, Ouwehand WH, Estcourt L, Harvala H, Roberts DJ, Wilkinson IB, Screaton N, Loman N, Doffinger R, Lyons PA, Morgan BP, Goodfellow IG, Klenerman P, Lehner PJ, Matheson NJ, Thaventhiran JED. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nat Commun. 2020 Dec 14;11(1):6385. doi: 10.1038/s41467-020-19761-2. PMID: 33318491; PMCID: PMC7736571.
In vitro protocol: 1. Humeniuk R, Mathias A, Kirby BJ, Lutz JD, Cao H, Osinusi A, Babusis D, Porter D, Wei X, Ling J, Reddy YS, German P. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. Clin Pharmacokinet. 2021 Mar 30:1–15. doi: 10.1007/s40262-021-00984-5. Epub ahead of print. PMID: 33782830; PMCID: PMC8007387.
In vivo protocol: 1. Humeniuk R, Mathias A, Kirby BJ, Lutz JD, Cao H, Osinusi A, Babusis D, Porter D, Wei X, Ling J, Reddy YS, German P. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. Clin Pharmacokinet. 2021 Mar 30:1–15. doi: 10.1007/s40262-021-00984-5. Epub ahead of print. PMID: 33782830; PMCID: PMC8007387. 2. Buckland MS, Galloway JB, Fhogartaigh CN, Meredith L, Provine NM, Bloor S, Ogbe A, Zelek WM, Smielewska A, Yakovleva A, Mann T, Bergamaschi L, Turner L, Mescia F, Toonen EJM, Hackstein CP, Akther HD, Vieira VA, Ceron-Gutierrez L, Periselneris J, Kiani-Alikhan S, Grigoriadou S, Vaghela D, Lear SE, Török ME, Hamilton WL, Stockton J, Quick J, Nelson P, Hunter M, Coulter TI, Devlin L; CITIID-NIHR COVID-19 BioResource Collaboration; MRC-Toxicology Unit COVID-19 Consortium, Bradley JR, Smith KGC, Ouwehand WH, Estcourt L, Harvala H, Roberts DJ, Wilkinson IB, Screaton N, Loman N, Doffinger R, Lyons PA, Morgan BP, Goodfellow IG, Klenerman P, Lehner PJ, Matheson NJ, Thaventhiran JED. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nat Commun. 2020 Dec 14;11(1):6385. doi: 10.1038/s41467-020-19761-2. PMID: 33318491; PMCID: PMC7736571.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x
Remdesivir, supplied by MedKoo, has been cited in below publications: 1. Pasupuleti RR, Tsai PC, Ponnusamy VK, Pugazhendhi A. Rapid determination of remdesivir (SARS-CoV-2 drug) in human plasma for therapeutic drug monitoring in COVID-19-Patients. Process Biochem. 2021 Mar;102:150-156. doi: 10.1016/j.procbio.2020.12.014. Epub 2020 Dec 25. PMID: 33390763; PMCID: PMC7762619. 2. Sawittree Sahakijpijarn, Chaeho Moon, Zachary N. Warnken, Esther Y. Maier, Jennie E. DeVore, Dale J. Christensen, John J. Koleng, Robert O. Williams, In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters, International Journal of Pharmaceutics: X, Volume 3, 2021, 100073, ISSN 2590-1567, https://doi.org/10.1016/j.ijpx.2021.100073. 3. Matthew A. Schaller, Yamini Sharma, Zadia Dupee, Duy Nguyen, Juan Uruena, Ryan Smolchek, Julia C. Loeb, Tiago N. Machuca, In vitro infection of human lung tissue with SARS-CoV-2: Heterogeneity in host defense and therapeutic response. BioRxiv. doi : https://doi.org/10.1101/2021.01.20.427541 4. Baggen J, Persoons L, Vanstreels E, Jansen S, Van Looveren D, Boeckx B, Geudens V, De Man J, Jochmans D, Wauters J, Wauters E, Vanaudenaerde BM, Lambrechts D, Neyts J, Dallmeier K, Thibaut HJ, Jacquemyn M, Maes P, Daelemans D. Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. Nat Genet. 2021 Mar 8. doi: 10.1038/s41588-021-00805-2. Epub ahead of print. PMID: 33686287.

1: Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. 2020 Apr 10. doi: 10.1007/s10067-020-05073-9. Epub ahead of print. PMID: 32277367.

2: Kakodkar P, Kaka N, Baig MN. A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). Cureus. 2020 Apr 6;12(4):e7560. doi: 10.7759/cureus.7560. PMID: 32269893; PMCID: PMC7138423.

3: Cao YC, Deng QX, Dai SX. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Med Infect Dis. 2020 Apr 2:101647. doi: 10.1016/j.tmaid.2020.101647. Epub ahead of print. PMID: 32247927; PMCID: PMC7151266.

4: Xie M, Chen Q. Insight into 2019 novel coronavirus - an updated intrim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis. 2020 Apr 1. doi: 10.1016/j.ijid.2020.03.071. Epub ahead of print. PMID: 32247050; PMCID: PMC7118633.

5: Reina J. Remdesivir, la esperanza antiviral frente al SARS-CoV-2 [Remdesivir, the antiviral hope against SARS-CoV-2]. Rev Esp Quimioter. 2020 Apr 1:reina01apr2020. Spanish. doi: 10.37201/req/098.2020. Epub ahead of print. PMID: 32239125.

6: Amirian ES, Levy JK. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health. 2020 Mar 27;9:100128. doi: 10.1016/j.onehlt.2020.100128. PMID: 32258351; PMCID: PMC7125341.

7: Zhang C, Huang S, Zheng F, Dai Y. Controversial treatments: An updated understanding of the coronavirus disease 2019. J Med Virol. 2020 Mar 26. doi: 10.1002/jmv.25788. Epub ahead of print. PMID: 32219882.

8: McCreary EK, Pogue JM. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. Open Forum Infect Dis. 2020 Mar 23;7(4):ofaa105. doi: 10.1093/ofid/ofaa105. PMID: 32284951; PMCID: PMC7144823.

9: Du B, Qiu HB, Zhan X, Wang YS, Kang HYJ, Li XY, Wang F, Sun B, Tong ZH. [Pharmacotherapeutics for the new coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):173-176. Chinese. doi: 10.3760/cma.j.issn.1001-0939.2020.03.005. PMID: 32164081.

10: Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020 Mar 9:AAC.00399-20. doi: 10.1128/AAC.00399-20. Epub ahead of print. PMID: 32152082.

11: Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, Ko WC, Hsueh PR. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect. 2020 Mar 4. doi: 10.1016/j.jmii.2020.02.012. Epub ahead of print. PMID: 32173241; PMCID: PMC7128959.

12: De Clercq E. New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. Chem Asian J. 2019 Nov 18;14(22):3962-3968. doi: 10.1002/asia.201900841. Epub 2019 Aug 7. PMID: 31389664.

13: Hoenen T, Groseth A, Feldmann H. Therapeutic strategies to target the Ebola virus life cycle. Nat Rev Microbiol. 2019 Oct;17(10):593-606. doi: 10.1038/s41579-019-0233-2. Epub 2019 Jul 24. PMID: 31341272.

14: Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC. Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019 Jul;167:45-67. doi: 10.1016/j.antiviral.2019.04.006. Epub 2019 Apr 8. PMID: 30974127; PMCID: PMC7132446.

15: Cardile AP, Warren TK, Martins KA, Reisler RB, Bavari S. Will There Be a Cure for Ebola? Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:329-348. doi: 10.1146/annurev-pharmtox-010716-105055. Epub 2016 Dec 7. PMID: 27959624.



Additional Information

(1). formulation for in vivo study (Author from NIH):
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104368/
....treated with 5 mg/kg remdesivir in vehicle solution (5 mg/mL 12% sulfobutylether-β-cyclodextrin in water and hydrochloric acid, pH3.5)

(2). formulation for in vivo study ( Author from CDC)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732787/
One group of animals received remdesivir (10 mg/kg) (Gilead Sciences) in vehicle solution [12% sulfobutylether-β-cyclodextrin in water and hydrochloric acid (pH 3.5)]